Novo to Present Liver Data on Wegovy and Investigational Efruxifermin
Novo plans to present liver data on Wegovy 2.4 mg and investigational efruxifermin at the 2026 AASLD meeting.
Related stories
Sunshine Oilsands Schedules Board Meeting on Quarterly Results
Sunshine Oilsands has scheduled a board meeting to approve its quarterly results.
M impact | EQUITY | Oct 29, 2026, 09:39 AM UTC
Alamos Gold Posts Higher Q3 Adjusted Net Earnings YoY
Alamos Gold reported higher adjusted net earnings year over year for the third quarter.
M impact | EQUITY | Oct 29, 2026, 09:38 AM UTC
三六零 Says Q3 Revenue Fell 3.9% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:38 AM UTC
Linde Q3 Revenue Rises 9% on Higher Pricing and Volumes
M impact | EQUITY | Oct 29, 2026, 09:38 AM UTC
MGRC Reports Fiscal Q3 Profit and EPS
MGRC reported fiscal 2026 third-quarter profit attributable to shareholders, up 2.84% year over year, and basic EPS.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
ROG Reports Fiscal Q3 Profit Growth of 161.3%
ROG reported fiscal 2026 third-quarter profit attributable to shareholders up 161.3% year over year, with basic EPS also reported.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC